Q4 EPS Estimate for United Therapeutics Reduced by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings estimates for United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $6.90 per share for the quarter, down from their previous estimate of $7.77. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2025 earnings at $7.85 EPS.

Several other equities analysts have also commented on the stock. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, TD Cowen upped their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $382.08.

United Therapeutics Stock Performance

Shares of UTHR opened at $370.58 on Thursday. The company has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 0.92 and a beta of 0.57. The company’s 50 day simple moving average is $361.93 and its 200 day simple moving average is $358.65. United Therapeutics has a 1 year low of $211.61 and a 1 year high of $417.82.

Insider Transactions at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 121,864 shares of company stock valued at $44,516,965 over the last 90 days. Corporate insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its stake in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Parallel Advisors LLC boosted its stake in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 30 shares during the last quarter. Anchor Investment Management LLC boosted its stake in United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 30 shares during the last quarter. Great Lakes Advisors LLC boosted its stake in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after acquiring an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its stake in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.